1. At a Glance – The “₹18 Share, ₹40 Ambition” Story

At ₹18.4 per share and a market cap that barely scrapes ₹3.87 crore, Fabino Enterprises is the kind of stock that doesn’t knock on your door — it whispers from the SME alley. Sales are running at ₹20.4 crore on a TTM basis, which already makes the valuation look like a clearance sale. But before you get excited and start imagining multibaggers dancing to dhol beats, pause. This company managed to post a TTM loss of ₹0.16 crore, an operating margin of -1.18%, and an annualised EPS that looks like it skipped leg day.

The latest half-yearly results (H1 FY26 ended September 2025) show revenue of ₹6.63 crore and a net loss of ₹0.19 crore. Yes, sales grew sharply YoY on a quarterly basis, but profits decided to take a U-turn, miss the exit, and fall into a ditch. ROCE is a modest 5.61%, ROE a sleepy 1.44%, and debt stands at ₹1.76 crore — not terrifying, but enough to keep the interest coverage at a nervy 0.75.

This is not a stock screaming “quality compounder.” This is a stock quietly asking, “Bhaiya, thoda patience milega?” Curious yet? Good. Let’s dig deeper.

2. Introduction – When Pharma, FMCG, Ayurveda, and Kirana Store Had a Group Chat

Fabino Enterprises is what happens when a company refuses to be boxed into one identity. Incorporated in 2011, it started life as a pharmaceutical-focused entity and has since shapeshifted into a multi-headed hydra: allopathic medicines, herbal products, wellness powders, edible oils, food commodities, and even agricultural ambitions.

In FY24, management didn’t just tweak the business model — they rewrote the entire syllabus. The main object clause was expanded to include everything from pickles and spices to agrochemicals, biotech products, veterinary medicines, and GMOs. If business diversification were an Olympic sport, Fabino would at least qualify for nationals.

The name change from Fabino Life Sciences Limited to Fabino Enterprises Ltd in FY24 was symbolic. This is no longer just “life sciences.” This is life, science, food, oil, agriculture, and vibes.

But here’s the catch: diversification is sexy only when execution keeps up. Otherwise, it becomes a buffet where nothing tastes great. So the real question is — is Fabino building an empire, or just collecting visiting cards from different industries?

3. Business Model – WTF Do They Even Do? (Explained Like You’re Smart but Lazy)

At its core, Fabino is a brand owner and marketer, not a hardcore manufacturer. The company markets pharmaceutical formulations for the domestic market using its own distribution network and sales force. Manufacturing of Ayurvedic formulations is done through loan licensing, with third-party manufacturers handling production while Fabino handles branding, packing, labelling, and sales.

On the pharma side, the product basket includes allopathic medicines like Amoxrag, Cefga, Fabpara, and Dexrog Syrup. Then there are herbal and ayurvedic products such as Ayush Kadha, Utrag Syrup, and Aurcis-Forte. COVID-era products like sanitizers, PPE kits, and masks also made an appearance — because of course they did.

Outside pharma, the company exports and markets FMCG and wellness products: coffee, malt powder, protein powder, hair shampoo, edible oils, and even staples like rice, wheat, sugar, and saffron. Brands like Fabino (pharma-focused) and Keepshine (hair care) sit under the umbrella.

In theory, this is an asset-light, scalable model. In practice, margins are thin, working capital is stretched, and execution risk is high. The company is trying to be Pharma, Patanjali, and a kirana wholesaler — all with a sub-₹4 crore market cap.

Does that sound ambitious or chaotic? Depends on how much coffee you’ve had.

4. Financials Overview – Half-Yearly Reality Check (H1 FY26 Locked)

Result Type Locked: Half-Yearly Results (H1 FY26)
Annualised EPS = Latest EPS × 2

Financial Comparison Table (₹ Crore)

Annualised EPS (H1 FY26): -1.80

Commentary time: revenue growth looks impressive on paper, but profitability collapsed faster than a cheap plastic chair at a wedding. Expenses overshot revenue, operating margin turned sharply negative, and the bottom line followed obediently.

Sales growth without profit growth is like running faster on a treadmill — impressive sweat, zero distance.

5. Valuation Discussion – Fair Value Range (Because Exact Numbers Are For Overconfident People)

Method 1: P/E Multiple

With negative annualised EPS (-1.80), traditional P/E valuation becomes meaningless. You can’t divide by sadness.

Method 2: EV/EBITDA

• Enterprise Value: ₹5.41 crore
• EBITDA (TTM): -₹0.24